- Price
- $11.32
- Day
- +5.11%
- Mkt Cap
- $1.27B
- 52W Range
- $7.95 – $28.25
- Volume
- 4.33M
- Beta
- 1.77
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-three research firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and one
Read full article
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates.
Read full article
Amova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 10.0% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,973,061 shares of the company's stock after selling 219,400 shares during the quarter. Amova Asset Management
Read full article
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Read full article